A phase II study of cisplatin, 5 fluorouracil (5-FU), radiation (RT) and celecoxib in patients with resectable esophageal cancer (EC): Updated results from the Hoosier Oncology Group (HOG) study

Ramaswamy Govindan,Naomi S. Fineberg,Howard L. McLeod,Kenneth A. Kesler,Nasser Hanna,C. Stoner,Jake Vinson,R. Mantravadi,Lawrence H. Einhorn

A phase II study of cisplatin, 5 fluorouracil (5-FU), radiation (RT) and celecoxib in patients with resectable esophageal cancer (EC): Updated results from the Hoosier Oncology Group (HOG) study

2004

Ramaswamy Govindan
Naomi S. Fineberg
Howard L. McLeod
Kenneth A. Kesler
Nasser Hanna
C. Stoner
Jake Vinson
R. Mantravadi
Lawrence H. Einhorn

4052 Background: EC commonly expresses cyclo-oxygenase II (COX-2). COX-2 inhibition results in decreased cell proliferation and potentiation of chemotherapy and radiation. We reported the prelimina...

Keywords:

Celecoxib
Fluorouracil
Radiation
Cisplatin
General surgery
Phases of clinical research
Esophageal cancer
Oncology
Medicine
Internal medicine
in patient
Cell growth
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations